US Stock Market Move | Lively Comes to Acquire AtaiBeckley Inc. for up to $3.8 Billion, with shares soaring over 30% at the opening.

On Thursday, AtaiBeckley Inc. (ATAI.US) soared more than 30% at the opening, reaching a new high for the year at $7.05 per share. On the news front, Eli Lilly (LLY.US) has agreed to acquire AtaiBeckley Inc. for up to $3.8 billion, highlighting the growing interest of major pharmaceutical companies in the once fringe area of psychedelic drug medicine. According to a statement on Thursday, Eli Lilly will pay $6.75 in cash per share, with an additional $2.50 per share if certain drug development milestones are reached. The base price represents a 26% premium over AtaiBeckley's closing price on Wednesday. AtaiBeckley is exploring options for the sale or partnership of its flagship drug, BPL-003. This deal further deepens Eli Lilly's long-term presence in the field of neuroscience drugs. This comes at a crucial moment in the development of psychedelic drugs. After lingering on the edge of drug development for many years, this field has recently seen success with Johnson & Johnson's Spravato, promising clinical trial results, and recent support from the Trump administration. Analysts suggest that sales in the psychedelic therapy market could reach $7 billion by 2032.